(Reuters) – PTC Therapeutics Inc said on Wednesday its experimental Huntington’s disease drug lowered mutated protein levels that cause the disease, citing interim data from a mid-stage study.
At 10 milligrams dose, the study showed as much as 30% dose-dependent reductions of the mutant protein that causes the disease that impairs a person’s ability to think, feel and move.
The company said the treatment also was well-tolerated and no serious adverse events were reported during the trial.
(Reporting by Khushi Mandowara in Bengaluru; Editing by Sriraj Kalluvila)
